Ebola hemorrhagic fever (EHF) is a severe disease caused by several species of Ebolavirus (EBOV), in the family Filoviridae. Prior to 2007, four species of EBOV had been identified, with two (Zaire ebola virus and Sudan ebolavirus) having caused significant disease outbreaks in humans. Outbreaks of EHF are associated with person-to-person transmission after the virus is introduced into humans from a zoonotic reservoir. During outbreaks the virus is commonly transmitted through direct contact with infected persons or their bodily fluids. The onset of EHF is associated with nonspecific signs and symptoms, including fever, myalgias, headache, abdominal pain, nausea, vomiting, and diarrhea. In the later stages of disease, overt hemorrhage has been reported in up to 50% of cases.
The presence of a fifth EBOV virus species, Bundibugyo ebolavirus (BEBOV) was identified after an outbreak of EHF in the Bundibugyo District of western Uganda in 2007.
Source:Recombinant protein corresponding to Ebolavirus (subtype Bundibugyo, strain Uganda 2007) Envelope Glycoprotein 1 (GP1), Ile 33-Gln 304 (Accession # ACI28624), expressed in HEK293 cells.
Subtype:Bundibugyo
Strain:Uganda 2007
Molecular Weight:~31.8kD
Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
仕様
Size：100ug
Source Antigen：Recombinant, HEK293 cells
Grade：Purified
Purity：~90% (SDS-PAGE)
Form：Supplied as a lyophilized powder in DPBS, pH 7.4. Reconstitute with 500ul sterile ddH2O.
